Suppr超能文献

西咪替丁在肝病患者中的药代动力学。

Pharmacokinetics of cimetidine in patients with liver disease.

作者信息

González-Martin G, Arancibia A, Fajuri M, Chesta J, Novoa X

出版信息

Int J Clin Pharmacol Ther Toxicol. 1985 Jul;23(7):355-8.

PMID:4030163
Abstract

Pharmacokinetics of cimetidine were studied after 200 mg i.v. doses in 7 patients with liver cirrhosis and in 10 healthy volunteers. Serial blood samples were obtained before and after drug administration over 12 hours. Cimetidine blood concentrations were determined by high pressure liquid chromatography (HPLC). The mean total body clearance in patients with cirrhosis (414.3 +/- 69.7 ml/min) was significantly less than that of subjects without liver dysfunction (501.1 +/- 37.9 ml/min) (p less than 0.01). However, the mean steady-state volume of distribution (1.34 +/- 0.41 l/kg vs 1.40 +/- 0.24 l/kg), volume of central compartment (0.51 +/- 0.11 l/kg vs. 0.45 +/- 0.05 l/kg), area volume of distribution (1.69 +/- 0.46 l/kg vs. 1.81 +/- 0.43 l/kg) and mean half-life (2.56 +/- 0.58 h vs. 2.68 +/- 0.43 h) did not demonstrate any significant changes. Renal clearance was significantly decreased from 389.5 +/- 41.9 ml/min in healthy subjects to 279.1 +/- 57.8 ml/min in cirrhotic patients (p less than 0.01). However, the mean extrarenal clearance was not changed in both groups. Modification of cimetidine dosage is therefore presumably not necessary in patients with compensated liver disease.

摘要

在7名肝硬化患者和10名健康志愿者中静脉注射200mg西咪替丁后,研究了其药代动力学。在给药前和给药后12小时内采集系列血样。采用高压液相色谱法(HPLC)测定西咪替丁血药浓度。肝硬化患者的平均全身清除率(414.3±69.7ml/min)显著低于无肝功能障碍受试者(501.1±37.9ml/min)(p<0.01)。然而,平均稳态分布容积(1.34±0.41l/kg对1.40±0.24l/kg)、中央室容积(0.51±0.11l/kg对0.45±0.05l/kg)、分布面积容积(1.69±0.46l/kg对1.81±0.43l/kg)和平均半衰期(2.56±0.58h对2.68±0.43h)均未显示出任何显著变化。健康受试者的肾清除率从389.5±41.9ml/min显著降低至肝硬化患者的279.1±57.8ml/min(p<0.01)。然而,两组的平均肾外清除率均未改变。因此,对于代偿性肝病患者,可能无需调整西咪替丁的剂量。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验